India has signed the agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) way back in 1 January 1995. It is now almost twenty years after signing the TRIPS agreement. According to the agreement all World Trade Organization (WTO) member countries must follow intellectual property rights regulation on inventions whether process or products, in all fields of technology, without any discrimination [1]. India was allowed a transition period of ten year from 1995 to 2005 as part of harmonization process to switch over from the then existing process patent to product patent. As a result India__ampersandsignrsquo;s Intellectual Property Rights (IPR) act 1970 has undergone three amendments in March 1999, June 2002 and April 2005 to comply with TRIPS principles. The new IPR Act 2005 has transformed the pharmaceutical industry from process patent to product patent, so also extended the product patent protection term from seven to twenty years. Besides this, the burden of proof of the process used in developing a drug now shifts to the defending company. The new product patent policy has become a challenge for Indian pharmaceutical companies. Companies have to invest heavily on the discovery of new drug molecules now as they can no longer use the process patent protection to re-engineer patented drugs. This has put enormous pressure on Indian pharmaceutical companies to remain innovative by investing in new drug research __ampersandsignamp; development (R__ampersandsignamp;D) for their own survival and growth. However, the research finds that there is no significant R__ampersandsignamp;D investment from Indian pharmaceutical companies to promote new drug molecule research despite twenty years into signing TRIPS agreement. The question now is __ampersandsignldquo;when will India get the pills?__ampersandsignrdquo;